Healthcare Industry News: cardiopulmonary
News Release - November 8, 2013
Sorin Group Announces First European Implant of Mitroflow Valsalva ConduitSorin Group’s innovative approach to aortic root surgery now available to European cardiac surgeons and their patients
MILAN--(Healthcare Sales & Marketing Network)--Sorin Group (SRN.MI), (Reuters Code: SORN.MI), a global medical company and a leader in the treatment of cardiovascular diseases, announced today that the first European implant of Mitroflow Valsalva Conduit was performed by Prof. Roberto di Bartolomeo, Chief of the Cardiac Surgery Department at Sant’Orsola-Malpighi Hospital, Bologna, Italy.
The Mitroflow Valsalva Conduit is the only aortic root surgery system with bovine pericardium valve available today. It consists of a vascular Valsalva conduit to be coupled with Sorin’s Mitroflow aortic pericardial heart valve. In addition to Mitroflow’s excellent hemodynamic performance and proven long-term durability, this innovative system provides cardiac surgeons with an easy and reproducible solution for replacing the ascending aorta and the diseased aortic valve in a single procedure.
“With Mitroflow Valsalva Conduit, Sorin Group offers a very intuitive approach to aortic root surgery procedures. I expect Sorin’s innovative approach will contribute to make aortic root system reconstructions more accurate and procedural times shorter, thus allowing surgeons to set even higher standards of care”, said Prof. Roberto di Bartolomeo.
Introduced in the U.S. at the end of 2012 following U.S. Food and Drug Administration (FDA) approval, the Mitroflow Valsalva Conduit has recently received CE mark and is now commercially available in Europe.
“Sorin Group is committed to providing clinicians around the world with innovative and integrated solutions targeted to improving patient care and health economic outcomes. We are very pleased to extend Mitroflow Valsalva Conduit’s commercial availability in Europe and thus allow a larger patient population to benefit from this unique reconstructive technology. The introduction of Sorin’s Mitroflow Valsalva Conduit in Europe represents a key milestone in Sorin’s strategic innovation plan”, said Michel Darnaud, Sorin Group, President, Cardiac Surgery Business Unit.
About Sorin Group
Sorin Group (www.sorin.com) is a global, medical device company and a leader in the treatment of cardiovascular diseases. The Company develops, manufactures, and markets medical technologies for cardiac surgery and for the treatment of cardiac rhythm disorders. With 3,750 employees worldwide, the Company focuses on two major therapeutic areas: Cardiac Surgery (cardiopulmonary products for open heart surgery and heart valve repair or replacement products) and Cardiac Rhythm Management (pacemakers, defibrillators and non invasive monitoring to diagnose and deliver anti-arrhythmia therapies as well as cardiac resynchronization devices for heart failure treatment). Every year, over one million patients are treated with Sorin Group devices in more than 80 countries.
For more information, please visit www.sorin.com.
Source: Sorin Group
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.